DXC vs. HQY, MEDP, BILI, WPP, LYFT, SEZL, AMTM, MARA, ETSY, and WSC
Should you be buying DXC Technology stock or one of its competitors? The main competitors of DXC Technology include HealthEquity (HQY), Medpace (MEDP), Bilibili (BILI), WPP (WPP), Lyft (LYFT), Sezzle (SEZL), Amentum (AMTM), Marathon Digital (MARA), Etsy (ETSY), and WillScot (WSC). These companies are all part of the "business services" industry.
DXC Technology vs. Its Competitors
DXC Technology (NYSE:DXC) and HealthEquity (NASDAQ:HQY) are both mid-cap business services companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitability, dividends, valuation, analyst recommendations, media sentiment, earnings, risk and institutional ownership.
HealthEquity has a net margin of 9.80% compared to DXC Technology's net margin of 3.02%. DXC Technology's return on equity of 19.36% beat HealthEquity's return on equity.
DXC Technology has a beta of 1.2, indicating that its share price is 20% more volatile than the S&P 500. Comparatively, HealthEquity has a beta of 0.49, indicating that its share price is 51% less volatile than the S&P 500.
96.2% of DXC Technology shares are held by institutional investors. Comparatively, 99.6% of HealthEquity shares are held by institutional investors. 0.6% of DXC Technology shares are held by company insiders. Comparatively, 1.5% of HealthEquity shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.
In the previous week, DXC Technology had 1 more articles in the media than HealthEquity. MarketBeat recorded 11 mentions for DXC Technology and 10 mentions for HealthEquity. HealthEquity's average media sentiment score of 1.04 beat DXC Technology's score of 0.33 indicating that HealthEquity is being referred to more favorably in the news media.
DXC Technology presently has a consensus target price of $17.00, suggesting a potential upside of 5.92%. HealthEquity has a consensus target price of $118.55, suggesting a potential upside of 14.96%. Given HealthEquity's stronger consensus rating and higher probable upside, analysts clearly believe HealthEquity is more favorable than DXC Technology.
DXC Technology has higher revenue and earnings than HealthEquity. DXC Technology is trading at a lower price-to-earnings ratio than HealthEquity, indicating that it is currently the more affordable of the two stocks.
Summary
HealthEquity beats DXC Technology on 11 of the 17 factors compared between the two stocks.
Get DXC Technology News Delivered to You Automatically
Sign up to receive the latest news and ratings for DXC and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding DXC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
DXC Technology Competitors List
Related Companies and Tools
This page (NYSE:DXC) was last updated on 7/9/2025 by MarketBeat.com Staff
Free DXC Stock Alerts